About the Abnormal Involuntary Movement Scale (AIMS)
The AIMS was developed in 1976, and has been used extensively in movement disorder assessments. It consists of ten distinct ratings that are observed both spontaneously and upon activation. Ratings one through seven score facial, extremity and trunk movements; items eight through ten are overall global judgments of severity, incapacitation and patient awareness. All ten ratings are scored on a zero to four scale with zero being rated as none, and four being rated as severe.
VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects. NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.
NBI-98854 may well be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and Tardive Dystonia.
Next Steps for NBI-98854
All of the clinical work to date for NBI-98854 has been conducted in Canada. The Company plans to open an IND
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved